Key facts
- This page summarizes Chris Nolet's Form 4 filing for Revance Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2024, 08:46.
Chris Nolet - 01 May 2024 Form 4 Insider Report for Revance Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 08:46:21 UTC
- Prior SEC filing
- 29 Jan 2024
- Next SEC filing
- 10 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dwight Moxie, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chris Nolet filed Form 4 for Revance Therapeutics, Inc. on 03 May 2024.
Change
- Previous filing in this sequence was filed on 29 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVNC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +52%
- Price
- $0.000000
- Shares after
- 43,606
- Date
- 01 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RVNC
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +23,458
- Change %
- Price
- $0.000000
- Shares after
- 23,458
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,458
- Exercise price
- $3.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
Footnote F2
The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.